IrelandIreland

Gene fuelled transporter causes breast cancer cells to self-destruct

28.02.2011

Belfast – Irish scientists have triggered self-destruction of breast cancer cells by transferring the gene, which encodes cytokine inducible Nitric Oxide Synthase (NOS-2 or iNOS), into the tumour cells. Clinical testing of the new gene cancer therapy, which relies on the iNOS-driven formation of toxic nitric oxide (NO) from L-arginine, is in reach within 5 years, the team headed by Dr Helen McCarthy from Queen's School of Pharmacy reported in the International Journal of Pharmaceutics (Feb. 28). For gene delivery, the researchers used a so-called Designer Biomimetic Vector, which targets the iNOS gene specifically to breast cancer cells. The idea is to turn the nanoparticles into a dried powder that could be easily transported and reconstituted before being given to patients. Dr McCarthy said: "A major stumbling block to using gene therapy in the past has been the lack of an effective delivery system. Combining the Designer Biomimetic Vector with the iNOS gene has proved successful in killing breast cancer cells in the laboratory. In the long term, I see this being used to treat people with metastatic breast cancer that has spread to the bones, ideally administered before radiotherapy and chemotherapy."

IrelandIreland

20.03.2012

While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided...

IrelandIreland

16.03.2012

Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved....

IrelandIreland

07.03.2012

Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and...

IrelandIreland

24.01.2012

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the...

IrelandIreland

13.12.2011

Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research...

IrelandIreland

07.12.2011

Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of...

IrelandIreland

05.12.2011

Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex...

IrelandIreland

01.10.2011

Athlone – Biopharma group Alkermes has established its new Irish corporate base following its merger with Elan Drug Tech­nologies. The a712m (US$960m) deal agreed back in May – which saw Alkermes acquire Elan’s Athlone-based drug...

Displaying results 1 to 10 out of 49

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-ireland/article/gene-fuelled-transporter-causes-breast-cancer-cells-to-self-destruct.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • EPIGENOMICS3.83 EUR23.5%
  • PAION3.05 EUR23.0%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-15.5%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 20.09.2014


Current issue

All issues

Product of the week

Products